149 related articles for article (PubMed ID: 37777577)
21. Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.
Saju SV; Radhakrishnan V; Ganesan TS; Dhanushkodi M; Raja A; Selvaluxmy G; Sagar TG
Med Oncol; 2019 Feb; 36(3):28. PubMed ID: 30725328
[TBL] [Abstract][Full Text] [Related]
22. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
[TBL] [Abstract][Full Text] [Related]
23. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
24. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.
Winter C; Zengerling F; Busch J; Heinzelbecker J; Pfister D; Ruf C; Lackner J; Albers P; Kliesch S; Schmidt S; Bokemeyer C
World J Urol; 2022 Dec; 40(12):2863-2878. PubMed ID: 35554637
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515).
Bastos DA; Gongora ABL; Dzik C; Jardim DL; Piva M; Carcano FM; Bertollo G; Trindade K; Fontes MS; Soares A; Reinert T; De Cassia Costamilan R; Villarroel RU; Watarai G; Gazola AA; Preto DDA; Mutti H; Bonalumi Dos Santos M; Mariano RC; Binotto M; Carvalho MM; Oliveira VPDC; Gomes R; Rebelatto TF; Schutz FA; Smaletz O; Fay AP
Clin Genitourin Cancer; 2023 Jun; 21(3):e104-e113. PubMed ID: 36509612
[TBL] [Abstract][Full Text] [Related]
26. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
27. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
29. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.
Ko JJ; Bernard B; Tran B; Li H; Asif T; Stukalin I; Lee M; Day D; Alimohamed N; Sweeney CJ; Bedard PL; Heng DY
J Clin Oncol; 2016 Mar; 34(7):714-20. PubMed ID: 26786931
[TBL] [Abstract][Full Text] [Related]
30. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
Fankhauser CD; Gerke TA; Roth L; Sander S; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Beyer J; Hermanns T
J Cancer Res Clin Oncol; 2019 Mar; 145(3):781-785. PubMed ID: 30637464
[TBL] [Abstract][Full Text] [Related]
31. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).
Rothermundt C; Thurneysen C; Cathomas R; Müller B; Mingrone W; Hirschi-Blickenstorfer A; Wehrhahn T; Ruf C; Rothschild S; Seifert B; Terbuch A; Grassmugg T; Woelky R; Fankhauser C; Kunit T; Fischer N; Inauen R; Kamradt J; Ziegler K; Haynes A; Jüni P; Gillessen S
Swiss Med Wkly; 2018; 148():w14640. PubMed ID: 30044478
[TBL] [Abstract][Full Text] [Related]
32. [High dose chemotherapy with autologous stem-cell support in germ cell tumors: The Instituto Português de Oncologia de Lisboa Francisco Gentil Series].
Brito M; Sanchez P; Velho S; Miranda N; Leal da Costa F; Ferreira I; Teixeira G; Guimarães A; Abecasis M; Passos Coelho JL
Acta Med Port; 2011; 24(4):533-44. PubMed ID: 22521011
[TBL] [Abstract][Full Text] [Related]
33. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
Oldenburg J; Aparicio J; Beyer J; Cohn-Cedermark G; Cullen M; Gilligan T; De Giorgi U; De Santis M; de Wit R; Fosså SD; Germà-Lluch JR; Gillessen S; Haugnes HS; Honecker F; Horwich A; Lorch A; Ondruš D; Rosti G; Stephenson AJ; Tandstad T
Ann Oncol; 2015 May; 26(5):833-838. PubMed ID: 25378299
[TBL] [Abstract][Full Text] [Related]
34. Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors.
Gariscsak PJ; Anson-Cartwright L; Atenafu EG; Jiang DM; Chung P; Bedard P; Warde P; O'Malley M; Sweet J; Glicksman RM; Hamilton RJ
Eur Urol Open Sci; 2022 Jun; 40():46-53. PubMed ID: 35638085
[TBL] [Abstract][Full Text] [Related]
35. CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors.
Fankhauser CD; Roth L; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Moch H; Bode PK; Beyer J; Hermanns T
BMC Cancer; 2019 Aug; 19(1):802. PubMed ID: 31412792
[TBL] [Abstract][Full Text] [Related]
36. Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours.
Lewin J; Soltan Ghoraie L; Bedard PL; Hamilton RJ; Chung P; Moore M; Jewett MAS; Anson-Cartwright L; Virtanen C; Winegarden N; Tsao J; Warde P; Sweet J; Haibe-Kains B; Hansen AR
BJU Int; 2018 Nov; 122(5):814-822. PubMed ID: 29726090
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
[TBL] [Abstract][Full Text] [Related]
38. Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review.
Ruf CG; Schmidt S; Kliesch S; Oing C; Pfister D; Busch J; Heinzelbecker J; Winter C; Zengerling F; Albers P; Oechsle K; Krege S; Lackner J; Dieckmann KP
World J Urol; 2022 Dec; 40(12):2889-2900. PubMed ID: 36107211
[TBL] [Abstract][Full Text] [Related]
39. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.
Winter C; Pfister D; Busch J; Bingöl C; Ranft U; Schrader M; Dieckmann KP; Heidenreich A; Albers P
Eur Urol; 2012 Feb; 61(2):403-9. PubMed ID: 22078334
[TBL] [Abstract][Full Text] [Related]
40. Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors.
Li X; Guo S; Wu Z; Dong P; Li Y; Zhang Z; Yao K; Han H; Qin Z; Zhou F; Liu Z
World J Urol; 2015 Sep; 33(9):1351-7. PubMed ID: 25471669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
